InvestorsHub Logo
Followers 30
Posts 1475
Boards Moderated 0
Alias Born 07/10/2013

Re: Echo20 post# 89963

Sunday, 05/11/2014 6:01:32 AM

Sunday, May 11, 2014 6:01:32 AM

Post# of 146240
No, no special information other than the following PR, among other positive PRs we've read in recent past:

December 9, 2013...

The Company’s drug development programs continue to progress satisfactorily. The broad-spectrum injectable FluCide™ anti-influenza drug is our most advanced drug candidate. Recently, the Company has announced that FluCide was found to be safe and well tolerated in a small non-GLP safety-toxicology study, even at the maximum feasible dosage level. In addition, the Company has successfully performed studies on the scale up of synthesis of FluCide.

source: http://www.nanoviricides.com/press%20releases/2013/NanoViricides%20Announces%20that%20its%20Annual%20Meeting%20was%20held%20on%20December%209th,%202013%20the%20CEO%20Presentation%20is%20available%20on%20the%20Redesigned%20Website.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News